ZA200602386B - 5-Arylpyrimidines as anticancer agents - Google Patents

5-Arylpyrimidines as anticancer agents

Info

Publication number
ZA200602386B
ZA200602386B ZA200602386A ZA200602386A ZA200602386B ZA 200602386 B ZA200602386 B ZA 200602386B ZA 200602386 A ZA200602386 A ZA 200602386A ZA 200602386 A ZA200602386 A ZA 200602386A ZA 200602386 B ZA200602386 B ZA 200602386B
Authority
ZA
South Africa
Prior art keywords
arylpyrimidines
anticancer agents
anticancer
agents
Prior art date
Application number
ZA200602386A
Other languages
English (en)
Inventor
Zhang Nan
Nguyen Thai Hiep
Ayral-Kaloustian Semiramis
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200602386B publication Critical patent/ZA200602386B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200602386A 2003-09-24 2006-03-23 5-Arylpyrimidines as anticancer agents ZA200602386B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50548703P 2003-09-24 2003-09-24

Publications (1)

Publication Number Publication Date
ZA200602386B true ZA200602386B (en) 2009-03-25

Family

ID=34393022

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200602386A ZA200602386B (en) 2003-09-24 2006-03-23 5-Arylpyrimidines as anticancer agents

Country Status (24)

Country Link
US (1) US7524849B2 (es)
EP (1) EP1663241B1 (es)
JP (1) JP2007506746A (es)
KR (1) KR20060089215A (es)
CN (1) CN1871009A (es)
AR (1) AR045811A1 (es)
AT (1) ATE432077T1 (es)
AU (1) AU2004275733A1 (es)
BR (1) BRPI0414736A (es)
CA (1) CA2539235A1 (es)
CO (1) CO5690592A2 (es)
DE (1) DE602004021269D1 (es)
EC (1) ECSP066457A (es)
GT (1) GT200400188A (es)
IL (1) IL174305A0 (es)
MX (1) MXPA06003207A (es)
NO (1) NO20061319L (es)
PA (1) PA8613201A1 (es)
PE (1) PE20050470A1 (es)
RU (1) RU2006107578A (es)
SA (1) SA04250303A (es)
TW (1) TW200512198A (es)
WO (1) WO2005030216A1 (es)
ZA (1) ZA200602386B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
CN101193884A (zh) 2005-06-13 2008-06-04 惠氏公司 微管蛋白抑制剂和其制备方法
CA2610416A1 (en) * 2005-06-13 2006-12-28 Wyeth Tubulin inhibitor and process for its preparation
US20110201496A1 (en) * 2006-03-27 2011-08-18 Joachim Rheinheimer Substituted 5-Hetaryl-4-Aminopyrimidines
CL2007002231A1 (es) * 2006-08-02 2008-04-11 Basf Ag Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
AR064852A1 (es) * 2007-01-11 2009-04-29 Basf Ag Pirimidinas sustituidas en posicion 2
WO2009007187A1 (de) * 2007-07-09 2009-01-15 Basf Se Substituierte 5-hetarylpyrimidine
HRP20240097T1 (hr) 2011-04-22 2024-03-29 Signal Pharmaceuticals, Llc Supstituirani diaminokarboksamid i diaminokarbonitril pirimidini, njihovi pripravci i postupci liječenja s njima
EP2903436B1 (en) * 2012-09-19 2019-07-17 The Trustees Of The University Of Pennsylvania Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
CN112451502B (zh) 2014-12-16 2023-10-27 西格诺药品有限公司 2-(叔丁基氨基)-4-((1r,3r,4r)-3-羟基-4-甲基环己基氨基)-嘧啶-5-甲酰胺的配制物
ES2882954T3 (es) 2014-12-16 2021-12-03 Signal Pharm Llc Usos médicos que comprenden métodos para la medición de la inhibición de la quinasa c-Jun N-terminal en la piel
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CA2993173C (en) 2015-07-24 2023-10-03 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
WO2019169111A1 (en) 2018-03-02 2019-09-06 The Trustees Of The University Of Pennsylvania [1,2,4]triazolo[1,5-a]pyrimidine compounds and use in stabilizing microtubules
EP4052759A4 (en) * 2019-11-01 2023-12-20 Unimatec Co., Ltd. FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND METHOD FOR THE PRODUCTION THEREOF
TW202132285A (zh) * 2019-11-13 2021-09-01 美商愛彼特生物製藥股份有限公司 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US88096A (en) * 1869-03-23 t h a y e r
US69242A (en) * 1867-09-24 Calvin pepper
US147744A (en) * 1874-02-24 Improvement in locomotive-furnaces
US116429A (en) * 1871-06-27 Improvement in dial-telegraph apparatus
US61889A (en) * 1867-02-05 Improvement in animal teaps
GB9700664D0 (en) 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
US6117876A (en) * 1997-04-14 2000-09-12 American Cyanamid Company Fungicidal trifluorophenyl-triazolopyrimidines
DE69934224T2 (de) 1998-04-27 2007-10-04 Kumiai Chemical Industry Co., Ltd. 3-arylphenylsulfid-derivate und insektizide und mitizide
US6156925A (en) * 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
US5986135A (en) * 1998-09-25 1999-11-16 American Cyanamid Company Fungicidal trifluoromethylalkylamino-triazolopyrimidines
SK17452002A3 (sk) * 2000-06-13 2003-06-03 Basf Aktiengesellschaft Fungicídne 5-fenyl substituované 2-(kyanoamino)pyrimidíny
US6670362B2 (en) * 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
EE200300448A (et) * 2001-03-15 2004-02-16 Basf Aktiengesellschaft 5-fenüülpürimidiinid, meetodid ja vaheühendid nende valmistamiseks ning nende kasutamine patogeensete seente tõrjeks
ATE297390T1 (de) * 2001-04-20 2005-06-15 Ciba Sc Holding Ag 4-amino-2-(2-pyridinyl)pyrimidine als mikrobizide wirksubstanzen
IL161893A0 (en) 2001-11-19 2005-11-20 Basf Ag 5-Phenylpyrimidines, agents comprising the same, method for production and use thereof
AU2003210217A1 (en) 2002-02-21 2003-09-09 Basf Aktiengesellschaft 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, method and intermediate products for the production and use thereof for combating noxious fungi
US7731985B2 (en) 2002-03-15 2010-06-08 Ciba Specialty Chemicals Corporation 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
KR101052482B1 (ko) 2002-11-21 2011-07-28 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 포스포티딜이노시톨(pi) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용

Also Published As

Publication number Publication date
MXPA06003207A (es) 2006-06-23
DE602004021269D1 (de) 2009-07-09
PE20050470A1 (es) 2005-10-03
EP1663241B1 (en) 2009-05-27
US20050075357A1 (en) 2005-04-07
IL174305A0 (en) 2008-02-09
US7524849B2 (en) 2009-04-28
AU2004275733A1 (en) 2005-04-07
JP2007506746A (ja) 2007-03-22
ECSP066457A (es) 2006-09-18
SA04250303A (ar) 2005-12-03
TW200512198A (en) 2005-04-01
NO20061319L (no) 2006-04-20
CN1871009A (zh) 2006-11-29
RU2006107578A (ru) 2007-10-27
CA2539235A1 (en) 2005-04-07
GT200400188A (es) 2005-05-02
PA8613201A1 (es) 2005-11-25
ATE432077T1 (de) 2009-06-15
EP1663241A1 (en) 2006-06-07
CO5690592A2 (es) 2006-10-31
AR045811A1 (es) 2005-11-16
BRPI0414736A (pt) 2006-11-21
KR20060089215A (ko) 2006-08-08
WO2005030216A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
IL174305A0 (en) 5-arylpyrimidines as anticancer agents
EP1622540A4 (en) FORMULATIONS FOR CELL-PLAN-DEPENDENT CANCER
HK1096824A1 (en) Substituted arylpyrazoles as parasticidal agents
HK1090374A1 (en) 6-Ä(substituted)phenylÜ triazolopyrimidines as anticancer agents
DE502004009243D1 (en) Spirocyclische cyclohexan-derivate
DE502004003476D1 (en) Standfuss
DE502004006683D1 (en) Injection-locked-oscillator-schaltkreis
DE502004011852D1 (en) Nspritzventil
GB0329907D0 (en) Compositions
EP1613352A4 (en) MICRO-AGREED COMPOSITIONS
DE112004002769D2 (en) Schienengeführtes transportsystem
GB0329597D0 (en) Compositions
DE502004012153D1 (en) Rotorspinnmaschine
EP1694640A4 (en) ANTI CANCER AGENTS
DE10394343D2 (en) Berührungslose biometrische erkennung
GB0313511D0 (en) Combination
GB0300602D0 (en) Compositions
EP1709976A4 (en) EMT-INDUCING MEDIUM
DE602004008281D1 (en) Avermectin-b1-monosaccharidderivative
GB0316857D0 (en) Compositions
AU2833P (en) Baltinrose Gaura lindheimeri
AU2834P (en) Baltinblus Gaura lindheimeri
IL164811A0 (en) Vitamin-targeted inaging agents
HRP20031088A2 (en) Motor-cultivator share
GB0300294D0 (en) Combination